In June 2022, Metabolic Support UK provided vital feedback to the UK NSC regarding the benefits of adding Tyrosinaemia Type One to the UK’s newborn screening panel. The UK NSC urgently reviewed this feedback amongst other evidence and has today recommended that Tyrosinaemia Type One should be added to the UK’s newborn screening panel.

This is an incredible achievement which may lead to:

A reduction in the number of babies with tyrosinaemia type 1 who experience severe liver disease in the early months of life.

A reduction the number of babies with tyrosinaemia type 1 who need a liver transplant in later life

We thank the UK NSC for their consideration of our feedback on this matter and will continue to work with this group as well as the Newborn Screening Collaborative to ensure that no one is left behind. Your Rare Condition. Our Common Fight.

This may take some time to roll out but we’ll ensure to keep you updated every step of the way!

Read more from the UK NSC by clicking the button below: